AM

Adam Muzikant

Chief Business Officer

Avilar Therapeutics

Boston, Massachusetts


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Avilar Therapeutics
Industry
biotechnology
Employees
28.0
Seniority
C suite
Annual Revenue
1000000.0
Total Funding
75000000.0
Latest Funding
Seed

Technologies

Nginx Bootstrap Framework WordPress.org Google Tag Manager Mobile Friendly Vimeo Render Remote Basis AI

Keywords

extracellular protein degradation targeted protein degradation asgpr targeting chimeras atac platform mtac platform biopharmaceutical development modular drug discovery pathogenic proteins protein degrader therapeutics endolysosome targeting hepatocyte internalization disease-causing proteins novel protein degraders drug discovery platform extra-cellular proteome bioinformatics in drug design protein ligand technology asgpr ligands m6pr receptor targeting first-in-class therapeutics immunology applications neurological disease treatments autoimmune therapies drug efficacy enhancement modular design for degraders patent protected technologies high affinity ligands target selection methodologies biophysical modeling in pharmacology drug development strategies therapeutic innovation protein pharmacokinetics advanced drug formulations clinical application of degraders pharmacological interactions biochemical pathways in medicine translational medicine advances medicinal chemistry innovations team of expert scientists scientific advisory excellence healthcare financing in biotech investor engagement in pharmaceuticals regulatory compliance in drug development scientific research advancements collaborative drug discovery market opportunities for biotech integrated healthcare solutions novel therapeutic pipelines

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans